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Background: Hepatocellular carcinoma is difficult to diagnose early, and most patients are 
already in the late stages of the disease when they are admitted to hospital. The total 5-year 
survival rate is less than 5%. Recent studies have showed that brucine has a good anti-tumor 
effect, but high toxicity, poor water solubility, short half-life, narrow therapeutic window, and a 
toxic dose that is close to the therapeutic dose, which all limit its clinical application. This study 
evaluated the effects of brucine immuno-nanoparticles (BIN) on hepatocellular carcinoma.
Materials and methods: Anionic polymerization, chemical modification technology, and pha-
coemulsification technology were used to prepare a carboxylated polyethylene glycol-polylactic 
acid copolymer carrier material. Chemical coupling technology was utilized to develop anti-
human AFP McAb-polyethylene glycol-polylactic acid copolymer BIN. The size, shape, zeta 
potential, drug loading, encapsulation efficiency, and release of these immune-nanoparticles 
were studied in vitro. The targeting, and growth, invasion, and metastasis inhibitory effects of 
this treatment on liver cancer SMMC-7721 cells were tested.
Results: BIN were of uniform size with an average particle size of 249 ± 77 nm and zeta 
potential of −18.7 ± 4.19 mV . The encapsulation efficiency was 76.0% ± 2.3% and the drug 
load was 5.6% ± 0.2%. Complete uptake and even distribution around the liver cancer cell 
membrane were observed.
Conclusion: BIN had even size distribution, was stable, and had a slow-releasing effect. BIN 
targeted the cell membrane of the liver cancer cell SMMC-7721 and significantly inhibited 
the growth, adhesion, invasion, and metastasis of SMMC-7721 cells. As a novel drug carrier 
system, BIN are a potentially promising targeting treatment for liver cancer.
Keywords: cancer targeting, hepatocellular carcinoma, nanoparticles, targeted drug delivery, 
anti-tumor effect
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor, and there 
is only one cancer that causes more deaths worldwide. The overall 5-year survival rate 
is less than 5%. Each year some 564,000 new cases are diagnosed, and 549,000 people 
die. The poor prognosis is mainly due to common portal vein tumor invasion, which 
can cause high rates of intrahepatic metastasis and postoperative recurrence. Even in 
the early stages after radical resection, the metastasis and recurrence rate is 61.5%.1–3 
Currently, the primary treatment for primary liver cancer is surgery resection.
Primary liver cancer is often accompanied by varying degrees of cirrhosis, which is 
reported in 70%–90% of all cases. The risk of cirrhosis is enormously increased with 
respect to liver cirrhosis due to the high sensitivity of the hardened liver to ischemia and 
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blood loss. Long-term hepatic inflow occlusion and massive 
blood loss can easily lead to postoperative acute liver failure. 
The overall surgical resection rate is 15%–20%.4,5 Ziser et al 
found that patients with cirrhosis undergoing surgeries had a 
perioperative complication rate of 30.1% and mortality rate of 
11.6%.6 Liver transplantation for the treatment of liver cancer 
can completely resect the tumor and also radically improve 
the liver function of the patient. Especially for unresectable 
liver cancer or patients who cannot undergo liver resection, 
liver transplantation is the only radical surgical treatment. 
Nevertheless, tumor recurrence and metastasis significantly 
restrict the feasibility of liver transplantation. Calne et al 
reported that 37.5% of patients receiving liver transplants 
died of tumor recurrence from 2 months to 5 years after the 
surgery. The 5-year survival rate was 18.6%.7
For patients who cannot tolerate surgery or bear a high 
risk of recurrence and metastasis after the surgery and 
transplantation, the alternative treatments include systemic 
and local chemotherapy. These can control tumor growth to 
some extent, but some side effects such as poor targeting, 
low sensitivity, short effecting time, and high toxicity all 
significantly restrict their clinical application.8–10 Therefore, 
the development of a new drug delivery system characterized 
by effective targeting of the cancer cells, strong anti-tumor 
effects, local drug accumulation, slow release, and lower 
systemic toxicity is the focus for liver cancer treatment and 
the prevention of recurrence and metastasis.
Brucine is a weak basic indole alkaloid. Its formula is 
C23H26N2O4 and its molecular weight is 394.47 Da. It is a 
white crystal that is highly toxic and odorless, with a very 
bitter taste. It is slightly soluble in water, is levorotatory, and 
is soluble in ether, chloroform, ethanol, methanol and other 
organic solvents. Its high toxicity, poor water solubility, 
short half-life, and low toxic dose for intravenous use limit 
its clinical application in cancer treatment.
Qin et al treated in vitro cultured human hepatoma cells 
SMMC-7721 with brucine and found that the inhibition 
rate grew as the amount of brucine increased. At a dosage 
of 320 µg/mL, the inhibition rate was close to 100%, which 
showed that brucine had a significant inhibitory effect on 
liver cancer cells. Further studies showed that brucine could 
induce cell apoptosis by increasing Fas expression.11 Deng 
et al found that brucine and its liposome complex showed 
significant growth inhibition on transplanted liver cancer in 
Heps tumor-bearing mice, and it stimulated the hematopoietic 
and immune systems. Liposomal brucine has targeting and 
slow-release effects, and showed more powerful anti-tumor 
effects than brucine monomer.12–14
Combining the drug-loaded nanoparticles with mono-
clonal antibodies (McAb) against human hepatocellular 
carcinoma, we produced a drug-nanoparticle-monoclonal 
antibody immune complex. With cellular-targeting capa-
bilities, McAb could carry the drug-loaded nanoparticle to 
specific sites and enhance the interaction between the drug 
and liver cancer cells, thus elevating local drug concentration 
and increasing drug efficacy. This study employed anionic 
polymerization and chemical modification technology to 
prepare a carboxylated polyethylene glycol-polylactic acid 
block copolymer material, used phacoemulsification technol-
ogy to prepare carboxylated polyethylene glycol-polylactic 
acid block copolymer brucine nanoparticles, and utilized 
chemical coupling technology to develop anti-human AFP 
McAb-polyethylene glycol-poly lactic acid copolymers with 
brucine immuno-nanoparticles. By culturing human liver can-
cer cells SMMC-7721 in vitro, as well as in matrix adhesion 
and transwell chamber experiments, we observed the effects 
of brucine immuno-nanoparticles on liver cancer cell growth, 
cell matrix adhesion, invasion, and migration ability.
Materials and methods
Materials
Brucine monomer (Chengdu Man Si Te Biotechnology 
Co, Ltd, batch number: 110706-200 505, purity .99%); 
5-fluorouracil(5-Fu) (Shanghai Xudong Haipu Pharmaceutical 
Co, Ltd, batch number: 090315); carboxylated polyethylene 
glycol-poly lactic acid block copolymer (PLA-PEG-COOH, 
molecular weight, 40 kDa) (Jiangsu Paige Bio Co, Ltd, 
PA20100302); mouse anti-human AFP monoclonal antibody 
(McAb, 70 kDa, Hangzhou Hua Biotechnology Co, Ltd); 
8% polyvinyl alcohol (PVA) aqueous solution, acetonitrile, 
methylene chloride, methanol, acetone, octanol, carbodiimide 
hydrochloride (EDAC) (Shanghai Xinhua Chemical Co, Ltd); 
goat anti-mouse IgG FITC (Shanghai Unitech Biotechnology 
Co, Ltd); human hepatocellular carcinoma SMMC-7721 cell 
line (provided by Shanghai Biological Sciences Institute 
affiliated to the Chinese Academy of Sciences); Tetrazolium 
salt (MTT), dimethyl sulfoxide (DMSO) (Sigma, Munich, 
Germany); Matrigel gel (BD Biosciences, Franklin Lakes, 
NJ); transwell (8 µm pore size; Corning, Inc, Corning, NY); 
fibronectin (Roche, Basel, Switzerland).
Methods
Preparation of the carboxylated polyethylene glycol-
  polylactic acid copolymers brucine nanoparticles
Anionic polymerization and chemical modification 
technology were used to prepare carboxylated polyethylene 
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glycol-polylactide block copolymer materials. The following 
were mixed into 120 mL of brucine nano-  emulsion: 0.8 g of 
oil phase carboxylated polyethylene glycol-polylactic acid 
block copolymer (PLA-PEG-COOH), 40 mg of brucine, 
16 mL of dichloromethane (CH2Cl2), 8% aqueous polyvinyl 
alcohol (PVA), 40 mL of aqueous solution, and 80 mL of 
pure water. The mixture was dispersed by a high shear cut-
ting homogenization machine, then dispersed under 12,000 
rpm speed shear, and emulsified five times (for 30 seconds 
each time) under 300 W ultrasound. The emulsion was then 
added to 80 mL of purified water and magnetically stirred 
at 700 rpm at room temperature for 6 hours to volatilize the 
CH2Cl2. The dried emulsion was centrifuged at 5000 rpm 
for 10 minutes to remove any aggregates. The brucine nano-
emulsion was then harvested by collecting the supernatant. 
The brucine nano-emulsion was put into an ultrafiltration tube 
(Millipore Amicon 100, 000; Millipore, Billerica, MA) and 
centrifuged at 3000 g for 30 minutes to concentrate the solu-
tion and remove free brucine. The solution was then washed 
with purified water and centrifuged with ultrafiltration again 
to obtain the brucine concentrate, which was stored at 4°C 
in the refrigerator.
Preparation of the anti-human AFP McAb- 
polyethylene glycol-polylactic acid copolymer BINs
Five milligrams of EDAC (carbodiimide hydrochloride) 
was added to 3 mL of brucine nanoparticle solution. The 
mixture was shaken for 15 minutes at 200 rpm, and   anti-
human AFP McAb (1 mg/mL) was added, oscillated at 
200 rpm for 3 hours at 4°C, and centrifuged at 10,000 rpm 
for 5 minutes. The product of this was washed three times 
in 0.01 M PBS (pH 7.4). Nanoparticles were isolated by 
ultrafiltration centrifugation, and the BINs were stored at 
4°C in the refrigerator.
Analysis of particle size and zeta potential
A PSS ZWL380 nano particle size analyzer (Particle Sizing 
Systems, Inc, Santa Barbara, CA) was used to measure BIN 
particle size, size distribution, and zeta potential by the 
dynamic light scattering method. The angle of observation 
was 90°, and the temperature of the measurement was 25°C.
Morphology
The prepared BIN suspension sample was put on aluminum 
foil, dried, and sprayed with platinum. A S4800 scanning 
electron microscope (Hitachi, Tokyo, Japan) was used 
to observe the morphology with an accelerating voltage 
of 1 kV .
Drug loading
Brucine acetonitrile solution (0.01 mg/mL) was prepared as 
the control solution. 0.1 mL of BIN concentrate was added 
to 5 mL of acetonitrile, and the concentrate was ultrasounded 
for 5 minutes to fully extract the brucine, then acetonitrile 
was added to make up the volume to 10 mL. After being 
shaken and centrifuged at 12,000 rpm for 20 minutes, the 
supernatant was collected to measure the UV absorption at 
263 nm wavelength, and the absorbance A2 was recorded. 
The UV absorption of the control solution was measured 
at a wavelength of 263 nm, and the absorbance (As) was 
recorded. The brucine content in the concentrate was 
calculated as (A2/As) in mg/mL.
In vitro drug release
The dialysis method was employed to determine the drug 
release rate of BIN in vitro.
To calculate the stability of the brucine in the release 
medium, 20 mg of brucine was diluted to 0.01 mg/mL with 
0.5% polyoxyethylene dehydrated sorbitol monooleate PBS 
solution. The solution was put into a water bath constant tem-
perature oscillator (37°C ± 0.5°C) in the dark and 1.0 mL was 
sampled at 0, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, and 60 hours, with 
20 µL of this sample used to measure the brucine content. 
The content at 0 hours was set as 100% and changes in the 
brucine content were measured.
To calculate the drug release of BIN in vitro, dialysis bags 
were placed in distilled water for 24 hours. Eight   milliliters 
of BIN suspension was put into the dialysis bags, the ends 
of the dialysis bags were clipped, and the bags were placed 
into the release medium with magnetic stirring (200 rpm). 
Of the solution, 1.0 mL was sampled at 0, 0.5, 1, 2, 4, 8, 12, 
24, 36, 48, and 60 hours, with 20 µL of this sample used 
to measure the brucine content. The data were corrected 
in accordance with the degradation curve in the release 
medium. Concentrations of the brucine in the sample were 
measured at different time points. The cumulative drug 
release percentage (Q) was calculated and the cumulative 
release curve was plotted.
Determination of monoclonal antibody on brucine 
immuno-particle surface
The bicinchoninic acid (BCA) method was used to measure 
the antibody content of samples. After the BSA standard 
protein solution (10 µg/mL–750 µg/mL) and BCA working 
solution were allowed to react, the solution’s absorbance 
at 562 nm was measured and the concentration-absorbance 
curve and the curve equation were obtained. Forty microliters 
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of BIN suspension reacted with the BCA working solution 
and its absorbance at 562 nm was determined. The concentra-
tion of the antibody on the brucine nanoparticles was then 
obtained using the curve equation.
Cell targeting and positioning
Human hepatoma cells (SMMC-7721) were diluted with 10% 
fetal calf serum medium (RPMI-1640) to a cell concentra-
tion of 1 × 105/mL. One milliliter of human hepatoma cells 
(SMMC-7721) was cultured in an incubator in 5% CO2 at 
37°C for 24 hours. The culture fluid was discarded and the 
cells were washed twice with 0.01 M PBS. Then 100 µL 
of BIN solution was added and the cells were incubated in 
5% CO2 at 37°C for 24 hours, after which the BIN solution 
was discarded and the cells were washed three times with 
0.01 M PBS. One hundred microliters of FITC-labeled goat 
anti-mouse antibody (20 µL stock solution + 80 µL 0.01 M 
PBS) was added. After incubation for 2 hours, the cells were 
washed three times with 0.01 M PBS. A Zeiss LSM 510 
META confocal microscope (Zeiss, Oberkochen, Germany) 
was used to observe the cells with 488 nm laser excitation.
Grouping
Based on the experimental requirements, eight groups were set 
up: a RPMI-1640 group, a PLA-PEG-COOH copolymer group, 
an anti-human AFP McAb group, an anti-human AFP McAb-
PEG-PLA block copolymer group, a 5-FU group, a   brucine 
group, a brucine nanoparticles group, and a BIN group.
Morphological changes of liver cancer cells
Human hepatoma cells SMMC-7721 were diluted with 10% 
fetal calf serum medium RPMI-1640 to a cell concentration 
of 4 × 104/mL. The cell suspension was seeded on a 96-well 
plate with 100 µL per well under conditions of saturated 
humidity, 5% CO2, and 37°C for 12 hours. After the medium 
was removed, 100 µL of 10% fetal calf serum RPMI-1640 
culture medium containing different drug concentrations 
was added to each well. The different drug concentrations 
were 0.5, 1.0, 1.25, 2.5, 5.0, 7.5, 10, 15, 20, 25, 30, 40, 80, 
160, 240, 320, 400, 480 µg/mL. Three wells were set up for 
each dose group.
The blank control group used 10% fetal calf serum 
medium RPMI-1640 and the control group used human 
hepatoma cells cultured with 10% fetal calf serum RPMI-
1640 culture medium. The content of PLA-PEG-COOH 
copolymer, anti-human AFP-McAb, and anti-human AFP 
McAb-PLA-PEG block copolymer nanoparticles cor-
responded to the amount of anti-human AFP -McAb and 
PEG-PLA block copolymer in the BIN. After placing the 
HCC cells under conditions of saturated humidity, 5% CO2, 
and 37°C for 72 hours, morphological changes as well as 
the growing state of cells were observed by inverted phase 
contrast microscope.
Cancer cell growth inhibition
After 72 hours of culture, 20 µL of MTT solution (5 mg/mL) 
was added to each well and cells were cultured for 4 hours 
under 37°C in the dark. Then the MTT-containing medium 
was removed and 150 µL DMSO was added to the culture 
dish to react for 10 minutes. The absorbance value A of the 
blank control group was detected at 570 nm and adjusted 
to zero. The inhibition rate was calculated by the following 
formula:
Cell growth inhibition rate = (1 – test-well average A value  
  /average A value of control wells) × 100%
Effects of BIN on cell adhesion of liver cancer cells
Serum-free 1640 was used to dilute Matrigel (100 µg/mL), 
and 25 µL of the solution was then added to each of the 
96 wells in the plate and left to dry in a biological safety 
cabinet at room temperature. Brucine, 5-FU, brucine nano-
particles, and BIN were applied to SMMC-7721 hepatoma 
cells for 72 hours, with each applied at five different concen-
trations: 20, 40, 80, 160, and 240 µg/mL. A cell suspension 
of 4.0 × 105 cells/mL was prepared and 100 µL was added 
to each well of a 96-well plate adhesion system containing 
Matrigel. Each of the concentration cell suspensions was 
added to three wells, and each plate included three empty 
holes that were left empty as the control (only 100 µL serum-
free 1640 was added in the adhesion system). The 96-well 
plates containing hepatoma cells were placed in an incubator 
at 37°C, with 5% CO2 for 2 hours. The plates were then gently 
washed three times with 0.01 M PBS to remove non-adhesive 
cells. Twenty microliters of MTT solution (5 mg/mL) was 
added to each well, and the plates were then placed in the 
incubator at 37°C, with 5% CO2 for 4 hours. PBS (0.01 M) 
was used to wash the plates three times, and 100 µL of DMSO 
solution was added to each well and mixed for 10 minutes. 
The optical density of each well was measured under 570 nm 
to indirectly determine the cell-matrix adhesion. The average 
adhesion rate and the standard deviation were obtained by 
calculating the adhesion rate of each experimental concentra-
tion and that of the three blank holes.
Experimental adhesion rate of each well = (OD value 
of each hole – average OD value of blank wells)/(average 
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OD value of control wells – average OD value of blank 
wells) × 100%
Effects of BIN on invasion of liver cancer cells
Serum-free 1640 was used to dilute Matrigel (100 µg/mL), which 
was added to the upper transwell chamber (50 µL/chamber) to 
dry in a biological safety cabinet at room temperature. Serum-
free 1640 was added, and after 90 minutes the liquid and 
uncombined Martigel were removed. Brucine, 5-FU,   brucine 
nanoparticles, and BIN at concentrations of 10, 20, 40, 80, 
160, and 240 µg/mL were applied to SMMC-7721 hepatoma 
cells for 72 hours. A cell suspension of 4.0 × 105 cells/mL 
was prepared and added to the upper transwell chamber 
(150 µL/chamber). Six hundred microliters of RPMI-1640 
containing 10 µg/mL fibronectin and 10% BSA serum was 
added to the lower transwell chamber. The transwell plates 
were then removed and placed in a 37°C incubator with 5% 
CO2 for 24 hours. The filter side of the upper chamber was 
then cleaned with a cotton swab and the filter was stabilized 
with ethanol and stained with H&E. The filter was carefully 
cut from the chamber and the cells that had migrated through 
the filter pores from the underside of the filter were counted 
in four high-power fields per insert, and average values were 
calculated based on five vision fields (the upper, lower, 
left, right, and central). For each migration condition, three 
replicates were performed.
Invasion rate = (Number of invasive cells in drug groups 
  /number of invasive cells in the control group) × 100
Effects of BIN on the cell movement of liver  
cancer cells
Serum-free 1640 was added to the upper transwell chamber 
(100 µL/chamber). Brucine, 5-FU, brucine nanoparticles, and 
BIN were used on SMMC-7721 hepatoma cells for 72 hours 
at concentrations of 10, 20, 40, 80, 160, and 240 µg/mL. 
A cell suspension of 4.0 × 105 cells/mL was prepared and 
added to the upper transwell chamber (150 µL/chamber). 
Six hundred microliters of RPMI-1640 containing 10 µg/mL 
fibronectin and 10% BSA serum was added to the lower 
transwell chamber, and the transwell plates were placed in 
a 37°C incubator with 5% CO2 for 24 hours. The filter side 
of the upper chamber was then cleaned with a cotton swab 
and the filter was stabilized with ethanol and stained with 
H&E. The filter was carefully cut from the chamber and 
the cells that had migrated through the filter pores from the 
underside of the filter were counted in four high-power fields 
per insert, and average values were based on five vision fields 
(the upper, lower, left, right, and central). For each migration 
condition, three replicates were performed.
Migration rate = (number of migrated cells in drug groups 
  /number of migrated cells in the control group) × 100
Statistical analysis
SPSS statistical software (v 13.0; SPSS, Inc, Chicago, IL) 
was used to analyze the data. Analysis of variance of the ran-
domized design was employed within the group, and analysis 
of the data covariance of the randomized block design was 
used to compare the difference between groups. P , 0.05 
was considered statistically significant.
Results and discussion
Preparation and properties of BIN
In this study, anionic polymerization, chemical modification 
technology, and phacoemulsification technology were used 
to prepare carboxylated polyethylene glycol-polylactic acid 
copolymer carrier material. Chemical coupling technology 
was utilized to develop anti-human AFP McAb-polyethylene 
glycol-polylactic acid copolymer BIN. BIN were successfully 
prepared and showed uniform size with an average particle 
size of 249 ± 77 nm and zeta potential of –18.7 ± 4.19 mV . 
The drug load was 5.6% ± 0.2% (Figures 1 and 2). Brucine 
was completely released within 2 hours. BIN were very stable 
in the medium with an accumulative release rate of over 80% 
in 24 hours and 100% in 48 hours (Figure 3).
Determination of monoclonal antibodies 
on BIN surface
BCA was used to determine the concentration of AFP mono-
clonal antibodies on BIN, and the concentration was 15 µg 
antibodies/mg nanoparticles.
Brucine
Anti-human
AFP McAb
PEG PLA
Anionic polymerization and
chemical modification technology 
Phacoemulsification technology
–COOH Chemical coupling
technology
Brucine
immnue
nanoparticles
Brucine
nanoparticles
PLA-PEG-COOH
block copolymer
–NH2
Figure 1 Synthesis scheme of brucine immuno-nanoparticles.
Abbreviation: PEG-PLA-COOH, carboxylated polyethylene glycol-polylactic acid 
block copolymer.
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Brucine intake by cancer cells  
and its positioning
BIN were evenly distributed around the liver cancer cell 
membrane, showing consistent ring shapes and good target 
positioning (Figure 4).
Liver cancer cell growth inhibition by BIN
Liver cancer cells in the blank control group showed adher-
ent growth, clear cell outline, uniform cell arrangement, and 
vigorous growth under each experimental concentration. As 
the dose of BIN increased, the number of liver cancer cells 
dropped. Liver cancer cells that were arranged in sparse, 
round pseudopodia disappeared, normal cell structures 
were lost, and cytoplasm “bubble” phenomena could be 
seen. Other effects such as cell shrinkage and cell peripheral 
refraction changes decreased adhesion capacity, and more 
cell debris could be found (Figure 5).
Negative control groups showed no significant growth 
inhibition on liver cancer SMMC-7721 cells. The difference 
between groups was not statistically significant (P . 0.05) 
after 72 hours. BIN had a significant inhibitory effect on 
the growth of hepatoma cells SMMC-7721, which was cor-
related with the drug concentration and showed a time and 
dose-dependent manner for 72 hours. The difference between 
the groups was statistically significant (F = 5.719, P , 0.01) 
(Figure 6). Compared with brucine and brucine nanoparticles, 
BIN had the strongest inhibitory effects on hepatoma cells 
SMMC-7721 and the IC50 was 28.2 µg/mL, close to that of 
5-FU (IC50, 16.7 µg/mL) (Figure 7).
Effects of BIN on cell adhesion of liver 
cancer cells
In the negative control group, increased drug concentration 
had no significant effect on human hepatoma SMMC-7721 
cell matrix adhesion. No significant difference was found 
between groups (F = 0.001, P . 0.05). 5-FU, brucine, 
brucine nanoparticles, and BIN all had significant inhibi-
tory effects on human hepatoma SMMC-7721 cell matrix 
adhesion after 72 hours. As drug concentration increased, 
the inhibition effects were enhanced. The difference between 
groups was statistically significant (F = 125.194, P , 0.01). 
500 nm
Figure 2 Scanning electron microscope image of brucine immuno-nanoparticles 
(100,000× magnification).
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Figure 3 Release curve of brucine immuno-nanoparticles in vitro. Brucine was 
completely released within 2 hours. Brucine immuno-nanoparticles were very stable 
in the medium with an accumulative release rate of over 80% in 24 hours and 100% 
in 48 hours.
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Figure  4  Cell  targeting  and  positioning  of  the  brucine  immuno-nanoparticles. 
Complete  uptake  and  even  distribution  of  the  brucine  immuno-nanoparticles 
around the liver cancer cell membrane after incubation for 4 hours (A) ring green 
fluorescence; (B) without laser excitation; 400× magnification.
ABC
Figure 5 Growth effect of brucine immuno-nanoparticles on liver cancer cells. Liver 
cancer cells shrank and pseudopodia disappeared at a brucine concentration of 
1.0 µg/mL in brucine immuno-nanoparticles for 72 hours in vitro (A).  The number of 
liver cancer cells dropped, and liver cancer cells were sparse and round at a brucine 
concentration of 40 µg/mL in brucine immuno-nanoparticles for 72 hours in vitro (B). 
Liver cancer cells showed cytoplasm “bubble” phenomena and low adhesion capacity, 
and more cell debris could be found at a brucine concentration of 160 µg/mL in 
brucine immuno-nanoparticles for 72 hours in vitro (C) (200× magnification).
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Compared with brucine and brucine nanoparticles, BIN had 
the strongest inhibition effects on liver cancer cell matrix 
adhesion (Figure 8).
Effects of BIN on invasion  
of liver cancer cells
In the negative control group, increased drug concentration 
had no significant effect on human hepatoma SMMC-7721 
cell invasion. No significant difference was found between 
groups (F = 0.380, P . 0.05). 5-FU, brucine, brucine nanopar-
ticles, and BIN all had significant inhibitory effects on human 
hepatoma SMMC-7721 cell invasion after 72 hours. As the 
drug concentration increased, the inhibition effects were 
enhanced. The difference between groups was statistically 
significant (F = 57.238, P , 0.01). Compared with brucine 
and brucine nanoparticles, BIN had the strongest inhibitory 
effect on liver cancer cell invasion (Figures 9 and 10).
Effects of BIN on cell movement  
of liver cancer cells
In the negative control group, increased drug concentration 
had no significant effect on human hepatoma SMMC-7721 cell 
migration. No significant difference was found between groups 
(F = 1.183, P . 0.05). 5-FU, brucine, brucine nanoparticles, 
and BIN all had significant inhibitory effects on human hepa-
toma SMMC-7721 cell migration after 72 hours. As the drug 
concentration increased, the inhibitory effects were enhanced. 
The difference between the groups was statistically significant 
(F = 51.237, P , 0.01). Compared with brucine and brucine 
nanoparticles, BIN had the strongest inhibitory effect on liver 
cancer cell migration. (Figures 11 and 12).
Many anti-cancer drugs that are clinically employed at 
present have many problems and side effects such as poor 
water solubility, short half-life, poor targeting of cancer cells, 
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effects on the hepatoma cells SMMC-7721 than brucine or brucine nanoparticles for 
72 hours. Time- and dose-dependent effects were observed.
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Figure 7 Half maximal inhibitory concentration (IC50) of the brucine immuno-
nanoparticles  on  liver  cancer  cells.  The  half  maximal  inhibitory  concentration 
of the brucine immuno-nanoparticles was lower than that of brucine or brucine 
nanoparticles. The IC50 of the brucine immuno-nanoparticles (28.2 µg/mL) was close 
to that of 5-FU (16.7 µg/mL).
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Figure 8 The matrix adhesive rate of the brucine immuno-nanoparticles on liver 
cancer cells. Compared with brucine and brucine nanoparticles, brucine immuno-
nanoparticles had the strongest inhibition effects on liver cancer cell matrix adhesion 
for 72 hours.
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Figure  9  The  number  of  cells  permeating  through  the  filter  pores  from  the 
underside of the filter after brucine immuno-nanoparticles were applied at various 
concentrations to liver cancer cells for 72 hours (200× magnification).  As the drug 
concentration increased, the number of cell invasions decreased. (A) 10 µg/mL; (B) 
20 µg/mL; (C) 40 µg/mL; (D) 80 µg/mL.
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Figure  10  The  invasion  rate  of  the  brucine  immuno-nanoparticles  on  liver 
cancer cells. Compared with brucine and brucine nanoparticles, brucine immuno-
nanoparticles had the strongest inhibition effects on liver cancer cell invasion after 
72 hours.
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high toxicity, and the suppression of bone marrow activity. In 
recent years, nanotechnology has been incorporated into the 
development of new nano-anti-cancer drugs which promise 
ideal targeting and sustained release. The concentration of the 
drug in the cancer-affected organ can be significantly increased, 
accompanied by significantly enhanced efficacy and reduced 
side effects. Thus, these drugs show promise in the treat-
ment of liver cancer.15 Wang et al used tanshinone IIA and 
tanshinone IIA nanoparticles in the treatment of tumor-bearing 
mice with transplanted liver cancer H22 cells. Compared 
with the control group, tanshinone IIA and tanshinone IIA 
nanoparticles significantly inhibited tumor growth, and at the 
same level of drug concentration, tanshinone IIA nanoparticles 
inhibited tumor growth significantly better than tanshinone IIA, 
as demonstrated by significantly increased tumor necrosis and 
apoptosis, and lower cyclin E expression. This indicated that 
tanshinone IIA nanoparticles were superior to tanshinone IIA.16 
The uptake of nanoparticles was affected by the size, shape, 
surface characteristics, medium concentration, incubation 
time, temperature, and many other factors.17–22
Combining drug-loaded nanoparticles with monoclonal 
antibodies against human hepatocellular carcinoma produces 
a drug-nanoparticle-monoclonal antibody immune complex. 
McAb can carry drug-loaded nanoparticles to specific target 
sites, thus enhancing specific cancer cell-drug combinations, 
increasing the drug concentration, and improving efficacy. 
Wu et al combined the highly specific anti-human liver acid 
ferritin monoclonal antibody with doxorubicin-poly butyl 
cyanoacrylate nanoparticles and prepared liver-specific 
doxorubicin immuno-nanoparticles. Experiments showed 
that the nanoparticles had a significantly longer half-life and 
high targeting in nude mice tumor inhibition experiments 
in vivo and cytotoxicity experiments in vitro. The drug 
accumulated in the liver tumor, greatly increasing the 
drug’s concentration, extending the time during which it is 
effective, enhancing the efficacy, and reducing toxicity to 
other organs.23 Liu et al connected anti-tumor monoclonal 
antibody HAb18 with mitoxantrone-bovine serum albumin 
nanoparticles and prepared liver-specific immuno-
nanoparticles, which could effectively combine with human 
liver cancer cells. In vitro studies indicated that the nano-
drug could significantly enhance the inhibition of human 
hepatoma SMMC-7721 cell growth.24 Chen et al wrapped 
doxorubicin in a phospholipid bilayer and prepared liver-
specific immuno-phospholipid nanoparticles, which showed 
greatly increased inhibition of human liver cancer cell 
growth compared with doxorubicin or an ordinary plasmid. 
Compared with liposomes, lipid nanoparticles significantly 
improved the inhibition rate in mice bearing nude human 
liver cancer. Nanoparticles significantly increased the 
targeting of tumors, elevated drug concentration, extended 
the time during which it was effective, and reduced 
doxorubicin toxicity to other organs.25
Alpha-fetoprotein (AFP) is a major plasma protein pro-
duced by the yolk sac and the liver during fetal development. 
Normal adult liver cells lose the ability to produce AFP, and 
serum concentration is less than 20 µg/L. Cancerous liver 
cells can synthesize a large quantity of AFP, so AFP may be 
used as a biomarker for primary liver cancers. Liver cancer 
cells expressing AFP show a tendency towards early vascular 
invasion and intrahepatic metastasis. For primary liver cancer 
detection, the sensitivity for AFP is 79% and the specificity 
is 78%. The presence of AFP mRNA in peripheral blood 
reflects the level of free circulating peripheral liver cancer 
cells and allows early diagnosis, differential diagnosis, as well 
as signaling cancer recurrence or metastasis.26–28   Anti-tumor 
drugs connected with anti-AFP monoclonal antibodies can 
destroy tumor cells while causing only minor injury to normal 
cells, so are playing an increasingly important role in HCC 
treatment.29–31
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Figure  11  The  number  of  cells  migrating  through  the  filter  pores  from  the 
underside of the filter after brucine immuno-nanoparticles were applied at various 
concentrations to liver cancer cells for 72 hours (200× magnification).  As the drug 
concentration increased, the cell migration decreased. (A) 10 µg/mL; (B) 20 µg/mL; 
(C) 40 µg/mL; (D) 80 µg/mL; (E) 160 µg/mL; (F) 240 µg/mL.
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Figure  12  The  migratory  rate  of  the  brucine  immuno-nanoparticles  on  liver 
cancer cells. Compared with brucine and brucine nanoparticles, brucine immuno-
nanoparticles had the strongest inhibitory effect on liver cancer cell migration.
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This study exploited the hydrophilic and biocompatible 
characteristics of polyethylene glycol-polylactic acid block 
copolymers, and developed polyethylene glycol-polylactic 
acid block copolymer brucine nanoparticles. These have a 
number of advantages including good sustained release and 
strong targeting, and overcomes the disadvantages of brucine 
such as high toxicity, wide distribution, and short half-life. 
For the first time, we used phacoemulsification technology 
to combine brucine and carboxylated polyethylene glycol-
polylactic acid block copolymers to produce brucine 
nanoparticles, and we coupled the C-terminal polyethylene 
glycol with anti-human AFP McAb to improve the link 
ability. The BIN was successfully prepared, and results 
showed that the BIN had a uniform size distribution. 
In experiments, brucine was completely released into 
the medium within 2 hours, while brucine in immuno-
nanoparticles was completely released within 48 hours. In 
vitro experiments showed that BIN specifically targeted 
the liver cell membrane and had stronger liver cancer cell 
growth inhibition properties than brucine in a time- and dose-
dependent manner. Regarding liver cancer cell inhibition, 
the IC50 of BIN was lower than that of brucine and brucine 
nanoparticles, and close to that of 5-FU. After 72 hours, 
an increased dose caused the number of liver cancer cells 
to reduce, pseudopodia disappeared, “bubble” phenomena 
appeared in the cytoplasm, cells shrank, cell peripheral 
refraction weakened, and adhesion capacity decreased.
Primary liver cancer invasion and metastasis is a multi-step 
and complex process involving a series of important changes 
including cell adhesion, matrix degradation, cell migration, 
proliferation, and angiogenesis, and leads to recurrence and 
metastasis which severely impair the effects and prognosis 
of treatment.4 Recurrence and metastasis are important 
biological behaviors of malignant tumors.   Malignant cell 
invasion and metastasis begin with intercellular adhesion loss 
after early local infiltration.   Laminin, fibronectin,   collagen, 
and other integrins located on the basement   membrane 
  surface combine with laminin receptors, fibronectin 
receptors,   collagen receptors, and integrin   receptors on 
the surface of the tumor cell, which allows a tumor cell to 
adhere to the basement membrane. A decrease is seen in the 
homogenous cell adhesion between tumor cells mediated by 
adhesion molecules, which promotes the   shedding of tumor 
cells. The heterogenous adhesion between tumor cells and 
the matrix increases.32–35 Extracellular matrix degradation and 
basement membrane damage is one of the key steps in the 
process of tumor invasion and metastasis. After a number of 
hours of close contact between tumor cells and the   basement 
membrane, tumor cells will directly induce host cells to 
secrete endothelial growth factors and epidermal growth fac-
tors, and activate endothelial cells to produce proteases which 
can digest laminin, fibronectin, proteoglycans, collagen, and 
other extracellular matrix components. The basement mem-
brane is degraded with local defects, allowing tumor cells to 
move deeper into the tissue.36,37 Induced by growth factors 
and chemokines, tumor cells continue to move deeper, and 
after dissolving interstitial connective tissues, tumor cells 
can eventually reach blood vessels. Tumor cells can pass 
through the wall of a blood vessel in the same way and so 
enter the circulatory system, which can lead to recurrence 
and metastasis.38 The mechanisms of tumor recurrence and 
metastasis are still unclear, and we have not yet identified 
specific molecular markers or developed preventive measures 
to be used before these occur.
In vitro studies found that BIN could effectively inhibit 
cell matrix adhesion, invasion, and migration of SMMC-7721 
human hepatocellular carcinoma cells in a dose-dependent 
manner. Brucine was superior to brucine nanoparticles in 
inhibiting cell matrix adhesion, invasion, and movement of 
SMMC-7721 cells, probably related to the nanoparticles’ 
slow drug release. Compared with brucine and brucine 
nanoparticles, BIN had the strongest inhibitory effects on 
cell matrix adhesion, invasion, and migration of human liver 
cancer SMMC-7721 cells. The results showed that brucine 
nanoparticles combined with anti-human AFP McAb had 
immunospecificity and increased drug-targeting effects, 
which promoted the specific interaction between the drug and 
the targeted cells. The drug concentration was significantly 
elevated around the tumor cells. The BIN with the applica-
tion of polyethylene glycol-polylactic acid copolymers as 
drug carriers were macrocyclic and had good biocompat-
ibility, large drug loading, wide drug range, good stability, 
and excellent bioavailability characteristics. Combining the 
monoclonal antibody with nano-anti-cancer drugs, we pro-
duced brucine immuno-targeting nanoparticles with greatly 
improved positioning and anti-tumor effects. Compared with 
brucine and brucine nanoparticles, BIN displayed more spe-
cific tumor cell targeting, increased local drug concentration, 
and effectively inhibited cancer cell growth, matrix adhesion, 
invasion, and metastasis. Therefore, BIN is a promising anti-
cancer-targeting drug for inhibiting growth, recurrence, and 
metastasis of hepatocellular carcinoma.
Conclusion
A targeted drug delivery system was successfully prepared 
and its in vitro effects examined. This research shows that 
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the BIN can specifically combine with liver cancer cells, 
target the liver cancer cell membrane, and exert anti-tumor 
effects. BIN inhibit the growth of human hepatoma SMMC-
7721 cells in a time- and dose-dependent manner. BIN have 
significant sustained release, high local drug concentration, 
longer duration of action, and improved efficacy. Compared 
with brucine and brucine nanoparticles, BIN displayed 
more specific tumor cell targeting, increased local drug 
concentration, and effectively inhibited cancer cell growth, 
matrix adhesion, invasion, and metastasis. BIN are a poten-
tially promising anti-cancer targeting drug for inhibiting 
the growth, recurrence, and metastasis of hepatocellular 
carcinoma.
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